Background Frequencies of EGFR and KRAS mutations in non-small cell lung cancer
(NSCLC) have predominantly been determined in East Asian and North American …

BACKGROUND: The aim of this study was to validate clinical utilization of routinely prepared
cytology specimens for molecular testing to detect EGFR or KRAS mutations in lung cancer …

Objectives Owing to novel therapy strategies in epidermal growth factor receptor (EGFR)-
mutated patients, molecular analysis of the EGFR and KRAS genome has become crucial …

Introduction: The detection of mutations in the epidermal growth factor receptor (EGFR)
gene, which predict sensitivity to treatment with EGFR tyrosine kinase inhibitors, represents …

Introduction In randomly assigned studies with EGFR TKI only a minor proportion of patients
with NSCLC have genetically profiled biopsies. Guidelines provide evidence to perform …

EGFR mutation frequencies in unselected Caucasian populations are unknown. This study
assesses the prevalence of EGFR mutations in an unselected population‐based cohort, and …

Introduction Lung cancer is the leading cause of cancer-related deaths worldwide. New
therapies targeting the epidermal growth factor receptor (EGFR) tyrosine kinase are …

The targeted treatment of advanced non-small-cell lung cancer (NSCLC) depends on
confirmation of activating somatic EGFR mutation. The aim of the study was to evaluate the …

Introduction: PIONEER (NCT01185314) was a prospective, multinational, epidemiological
study of epidermal growth factor receptor (EGFR) mutations in patients from Asia with newly …

Introduction Testing for the epidermal growth factor receptor (EGFR) gene mutations
requires considerable multidisciplinary experience of clinicians (for appropriate patient …